Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

1,600

Participants

Timeline

Start Date

November 30, 2020

Primary Completion Date

August 31, 2021

Study Completion Date

September 30, 2021

Conditions
COVID-19 Prevention
Interventions
BIOLOGICAL

Gam-COVID-Vac

Vaccine for intramuscular injection

OTHER

Placebo

Placebo comparator

Trial Locations (23)

Unknown

S N Medical College, Agra

MGM Medical College and Hospital, Aurangabad

KLE Prabhakar Kore Hospital, Belagavi

Apollo Hospital, Delhi

Batra Hospital, Delhi

HIMSR with CHRD-SAS, Delhi

ESIC Medical College & Hospital, Faridabad

AIG hospital, Hyderabad

Maharaja Agrasen Superspecialty Hospital, Jaipur

GSVM Medical College, Kanpur

Peerless Hospital, Kolkata

Atharva Hospital, Lucknow

St. George's Hospital, Mumbai

JSS Hospital, Mysore

INCLEN trust and Gurunanak Hospital, Palwal

PIMS, Puducherry

BJ Sassoon Hospital, Pune

KEM Hospital, Pune

Noble Hospital Private Limited, Pune

BAPS hospital, Sūrat

Rhythm Heart Institute, Vadodara

Sumandeep Vidyapeeth, Vadodara

Christian Medical College, Vellore

All Listed Sponsors
collaborator

Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

OTHER

collaborator

Russian Direct Investment Fund

INDUSTRY

collaborator

CRO: JSS Medical Research India Pvt. Ltd.

UNKNOWN

lead

Dr. Reddy's Laboratories Limited

INDUSTRY